CliffBio
small molecule

VOSTALLY

RAMIPRIL

Loss of exclusivityAugust 2039latest FDA-listed patent expiry
CompanyRosemont Pharmaceuticals →View the full company profile on CliffBio

Drug detail

Brand nameVOSTALLY
Active ingredientRAMIPRIL
Strength1MG/ML
Dosage formSOLUTION
RouteORAL
ModalitySmall molecule
FDA approvalJuly 2025
Marketing statusDISCN

Listed patents

PatentExpiresType
12343338August 2039product

More from Rosemont Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

VOSTALLY patent cliff — loss of exclusivity August 2039 | CliffBio